{"id":"mc2-01-vehicle","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"No information is available to provide a deeper explanation of the mechanism.","oneSentence":"No mechanism of action is available for MC2-01 vehicle.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:24.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07357831","phase":"PHASE3","title":"A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-12-26","conditions":"Plaque Psoriasis","enrollment":537},{"nctId":"NCT03308799","phase":"PHASE3","title":"A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2017-10-03","conditions":"Psoriasis Vulgaris","enrollment":794},{"nctId":"NCT03802344","phase":"PHASE3","title":"This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-12-12","conditions":"Psoriasis Vulgaris","enrollment":498},{"nctId":"NCT03899064","phase":"PHASE1","title":"Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-13","conditions":"Photoallergy","enrollment":58},{"nctId":"NCT03892564","phase":"PHASE1","title":"Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-27","conditions":"Phototoxicity","enrollment":35},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":152993,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MC2-01 vehicle","genericName":"MC2-01 vehicle","companyName":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","companyId":"hangzhou-zhongmei-huadong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}